Summary
Boston Scientific Corporation's (BSX) third quarter 2005 results, as reported in their 10-Q filing dated November 7, 2005, indicate a company actively engaged in its operations, with financial reporting up-to-date. The company had 819,484,069 shares of common stock outstanding as of September 30, 2005, highlighting its significant market capitalization. As an accelerated filer, BSX adheres to regular and timely SEC reporting, suggesting a mature and established corporate presence. The filing confirms BSX is not a shell company, reinforcing its status as an active operating entity within the medical technology sector. While specific financial performance metrics such as revenue, net income, or earnings per share are not detailed in the provided excerpt, the filing's core purpose is to disclose its ongoing reporting compliance and share structure. Investors reviewing this document should note the company's commitment to regulatory standards and its substantial share count. Further analysis would require accessing the full financial statements within the 10-Q to understand the operational and financial performance for the quarter ending September 30, 2005.
Key Highlights
- 1Boston Scientific Corporation (BSX) filed its quarterly report (10-Q) for the period ending September 30, 2005, on November 7, 2005.
- 2The company confirmed it has met all reporting requirements for the preceding 12 months and the past 90 days.
- 3BSX is classified as an accelerated filer, indicating consistent and timely SEC disclosures.
- 4The report explicitly states that BSX is not a shell company, confirming its operational status.
- 5As of September 30, 2005, there were 819,484,069 shares of common stock outstanding.
- 6The company's principal executive offices are located in Natick, Massachusetts.